Top 200 generic drugs by units in 2006
MORE ARTICLES IN THIS ISSUE
A major change in the treatment of advanced or metastatic colon cancer has been made in a new update from the National Comprehensive Cancer Network (NCCN). The network's "Clinical Practice Guidelines in Oncology: Colon Cancer," published in January, were revised to reflect new scientific data and expert judgment.
Pharmacists appear pleased with the Food & Drug Administration's recent decision to allow orlistat 60-mg capsules to go over the counter (OTC) in the United States. (See Latebreakers, Feb. 19.) The OTC version, to be marketed by GlaxoSmithKline beginning this summer under the brand name alli, is for use by overweight adults 18 years and older in conjunction with a reduced-calorie, low-fat diet.
Editor's note: Throughout 2007, this column, which takes a look at some of the most important moments in the history of pharmacy, will appear in each issue as part of our sesquicentennial celebration. Tied with this column is a pharmacy history contest, which we are urging all readers to participate in. Monthly questions based on this column, will be posted on the Drug Topics anniversary microsite. Contestants are eligible to win a Visa gift card of $250. For details about the contest, go to www.drugtopics.com.
While I respect Greg Powell's opinion about the link between mercury and Alzheimer's disease (Viewpoint, Jan. 22), I worry that his rhetoric will further feed the anti-vaccine frenzy, particularly among parents who want to blame autism on vaccines, i.e., thimerosal, and refuse to have their children or themselves vaccinated.